Holen Sie sich die Stockscreener-App
4.375
2.71%
0.135
Handel nachbörslich:
4.36
-0.015
-0.34%
Schlusskurs vom Vortag:
$4.24
Offen:
$4.37
24-Stunden-Volumen:
1.53M
Relative Volume:
0.74
Marktkapitalisierung:
$383.13M
Einnahmen:
$30.91M
Nettoeinkommen (Verlust:
$-209.47M
KGV:
-1.3146
EPS:
-3.3279
Netto-Cashflow:
$-147.13M
1W Leistung:
+4.94%
1M Leistung:
-26.31%
6M Leistung:
-59.03%
1J Leistung:
-47.59%
1-Tages-Spanne:
$4.265
$4.50
1-Wochen-Bereich:
$4.00
$4.50
52-Wochen-Spanne:
$4.00
$11.24
Verastem Inc Stock (VSTM) Company Profile
Firmenname
Verastem Inc
Sektor
Branche
Telefon
(781) 292-4200
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
4.36 | 372.58M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2026-02-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-31 | Bestätigt | BTIG Research | Buy |
| 2024-09-30 | Eingeleitet | Guggenheim | Buy |
| 2023-11-21 | Fortgesetzt | BTIG Research | Buy |
| 2023-09-27 | Eingeleitet | B. Riley Securities | Buy |
| 2023-06-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-07 | Fortgesetzt | Alliance Global Partners | Buy |
| 2022-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-09 | Eingeleitet | Truist | Buy |
| 2021-07-01 | Eingeleitet | Alliance Global Partners | Buy |
| 2021-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-06-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Eingeleitet | BTIG Research | Buy |
| 2018-05-02 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2015-09-29 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2015-09-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Herabstufung | Mizuho | Buy → Neutral |
| 2015-09-28 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-05-12 | Bestätigt | UBS | Buy |
| 2015-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-01-23 | Bestätigt | ROTH Capital | Buy |
| 2014-07-08 | Fortgesetzt | Oppenheimer | Perform |
| 2014-02-11 | Eingeleitet | Mizuho | Buy |
Alle ansehen
Verastem Inc Aktie (VSTM) Neueste Nachrichten
Verastem Oncology Appoints Michael P. Bailey to Board of Directo - GuruFocus
Verastem (VSTM) stockholders back board slate, equity plans and auditor at 2026 meeting - Stock Titan
Verastem Oncology appoints Michael Bailey to board - Investing.com
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors - Yahoo Finance
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Verastem Q1 earnings call highlights - MSN
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Verastem Q3 2025 Earnings Preview - MSN
Foresite (VSTM) holds 3,146,631 shares, reporting 3.6% stake - Stock Titan
Armistice Capital 5.23% stake in Verastem (VSTM) via managed fund - Stock Titan
RTW Funds, Roderick Wong Report 9.99% of Verastem (VSTM) - Stock Titan
Balyasny-affiliated holders report 1.36M shares in Verastem (VSTM) - Stock Titan
Verastem Oncology announces management changes - MSN
VSTM Maintained by Mizuho -- Price Target Lowered to $14.00 - GuruFocus
MSN Money - MSN
Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating - Moomoo
Verastem, Inc. drives patient-focused efforts in rare ovarian cancer awareness - Traders Union
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
Press Release: Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates - Moomoo
Verastem Oncology to Present at Upcoming Investor Conferences - Barchart.com
TradingKey - TradingKey
Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results - simplywall.st
Verastem, Inc. (NASDAQ:VSTM) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
VSTM Slides As Verastem Inc. Selling Pressure Builds - timothysykes.com
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $18 - Moomoo
Verastem Q1 Earnings Call Highlights - Barchart
Verastem (VSTM) Q4 Revenue Reaches US$17.5 Million Yet Heavy Losses Reinforce Bearish Views - Sahm
Verastem, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VSTM) 2026-05-09 - Seeking Alpha
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Verastem Inc Earnings Call Highlights Growth And Risk - TipRanks
Verastem (VSTM) Q1 2026 Earnings Transcript - AOL.com
VSTM Maintained by BTIG -- Price Target Lowered to $18.00 - GuruFocus
(VSTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Q1 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Verastem stock price target lowered to $18 by BTIG on revenue miss - Investing.com Canada
New rare ovarian cancer guide aims to ease diagnosis-to-care hurdles - Stock Titan
MA-VERASTEM-ONCOLOGY - Black Hills Pioneer
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer - ChartMill
Verastem Q1 2026 Earnings Call Transcript - MarketBeat
Verastem: Q1 Earnings Snapshot - theheraldreview.com
Verastem, Inc. (VSTM) Stock Analysis: Exploring A Potential 189% Upside For Investors - DirectorsTalk Interviews
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss - ChartMill
Verastem (VSTM) Reports $18.7 Million in Q1 2026 Revenue with Po - GuruFocus
Earnings call transcript: Verastem Q1 2026 shows strong revenue growth By Investing.com - Investing.com Australia
Earnings call transcript: Verastem Q1 2026 shows strong revenue growth - Investing.com
Verastem (VSTM) reports Q1 loss, misses revenue estimates - MSN
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Verastem, Inc. posts first quarter 2026 earnings, updates on RAS MAPK pathway pipeline - Traders Union
Finanzdaten der Verastem Inc-Aktie (VSTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Verastem Inc-Aktie (VSTM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Paterson Dan | President and CEO |
Feb 04 '26 |
Sale |
6.69 |
970 |
6,489 |
612,919 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):